Standout Papers

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung ... 2015 2026 2018 2022 4.8k
  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial (2015)
    Roy S. Herbst, Paul Baas et al. The Lancet

Immediate Impact

4 by Nobel laureates 12 from Science/Nature 82 standout
Sub-graph 1 of 20

Citing Papers

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
2023 Standout
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
2022 Standout

Works of Ellie Im being referenced

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout

Author Peers

Author Last Decade Papers Cites
Ellie Im 4751 3019 638 1063 28 5.4k
Sanatan Saraf 3208 1485 439 790 43 4.1k
Fadi Braiteh 4087 1972 916 1126 73 5.5k
Marcus Ballinger 4914 2640 714 1381 54 6.2k
Sachet A. Shukla 3504 1502 1423 2264 47 5.4k
Reshma Rangwala 6851 4324 1125 1768 40 8.9k
Jean-Pascal Machiels 1999 2365 829 976 36 4.4k
Catherine Dubos Arvis 4670 3115 576 1010 16 5.2k
Andréa Varga 2934 1203 540 800 107 4.4k
Jennifer H. Yearley 3642 1349 657 2595 56 5.5k
Helen K. Angell 3924 1843 1381 2661 37 6.3k

All Works

Loading papers...

Rankless by CCL
2026